阿卡波糖与达格列净治疗2型糖尿病的临床效果及药物不良反应分析

打开文本图片集

中图分类号：R587.1文献标识码：A

DOI：10.3969/j.issn.1006-1959.2025.12.029 文章编号：1006-1959（2025）12-0136-04

Analysis of Clinical Effect and Adverse DrugReactionsof Acarboseand Dapagliflozin intheTreatmentof Type2DiabetesMellitus

ZHU Jian

（DepartmentofPharmacy，Yanshan CountyHospitalofTraditionalChinese Medicine，Yanshan3345o，Jiangxi，China）

Abstract：ObjectieToalyethenicalefectnddversedgreactiosofcarboenddapaglfoinintetreatmentoftyabee mlitus（D.etosigdoerableto63sitdtdtsotitalofdioal ChineseMediefroJauarytoDceber3eredivideditoarboseoup31patints）nddapaglflingrou32patints）hc wertreatediabdalsiellccodosptelodcole bldcoee） fluctuationdeelefccusiGE）filfes）htsted reactionswerecomparedbetweethetogroupsesultsereasnsiificantdiereceinbloodglucosecomplancerateandldglucoe compliance time between the two groups（ P>0 0.05）.The indexesofFPG，2hPBGand HbAlcinthetwo groups werelower than those before treatment （ P< 0.05），butthere wasnosignificant diffrence inFPG，2hPBGandHbAlc between the two groupsafter treatment（ P> 0.05）. The values of MAGE and MODD in the dapagliflozin group were lower than those in the acarbose group（ P <0.05）.The bodyweight and waist circumference of the two groupsaftertreaeerelesstantoefotreantndodytandistfereeoftapalifoplesta those of the acarbose group（ P<0.05 ）.The incidence of adverse drug reactions in dapagliflozin group（ 3.13% ）was lower than that in acarbose group （19.35 % ）（ P⋅

Keywords：Typedabetesmelitus;Acarbose;Dapaglifloin;HypoglycemicfcacyAdversereactions;Weight;Wistiuence

2型糖尿病（type2diabetesmellitus，T2DM）为我国高发内分泌疾病，以糖代谢紊乱为典型特征，其病情可累及多个器官组织，引发心、脑、肾等血管系统并发症，严重威胁患者身心健康及生存质量[2]。（剩余5030字）